BTK

Assets acting on this target.

Class
BTK inhibitor

Bruton's tyrosine kinase (BTK) is an intracellular signaling enzyme expressed mainly in B lymphocytes and related immune cells. It sits downstream of the B-cell receptor, a surface protein complex that recognizes antigens and triggers a cascade controlling B-cell survival, proliferation, and antibody production. In certain B-cell cancers, this signaling is chronically active, driving malignant cell growth; in autoimmune and allergic conditions, overactive B-cell and mast-cell signaling through BTK contributes to antibody-mediated tissue damage and inflammation. Inhibiting BTK interrupts this signaling relay, reducing abnormal B-cell proliferation or dampening immune activation, depending on the disease context. BTK inhibitors are small molecules that occupy the enzyme's active site; some bind irreversibly through a covalent chemical bond, while others bind reversibly, without forming a permanent attachment. Reversible binding can be useful when cancer cells develop mutations at the usual binding site that block covalent drugs, or when a shorter, more controllable duration of enzyme inhibition is desired. Because BTK also participates in normal immune defense and platelet function, its inhibition carries trade-offs between therapeutic benefit and effects on infection risk or bleeding tendency. This mechanism broadly matters across B-cell malignancies and select autoimmune and allergic diseases.

By indication

Related mechanisms

BTK drugs compared

5 drugs, stage by indication
5 drugs acting on BTK: developer, modality, furthest stage and stage in each indication. Furthest stage first.
DrugDeveloperModalityFurthest stageStage by indication
AcalabrutinibAstraZenecasmall molecule (BTK inhibitor)ApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Mantle Cell Lymphoma; Approved in Relapsed/Refractory Chronic Lymphocytic Leukemia; Phase 3 in Diffuse Large B-Cell Lymphoma
IbrutinibAbbVie, Johnson & Johnsonsmall moleculeApprovedApproved in Chronic Graft-versus-Host Disease; Approved in Chronic Lymphocytic Leukemia; Approved in Graft-versus-Host Disease; Phase 3 in Diffuse Large B-Cell Lymphoma; Phase 3 in Mantle Cell Lymphoma
PirtobrutinibEli Lillysmall moleculeApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Mantle Cell Lymphoma; Approved in Relapsed/Refractory Chronic Lymphocytic Leukemia; Phase 1 in Multiple Myeloma
rilzabrutinibSanofismall moleculeApprovedApproved in Immune Thrombocytopenia; Phase 2 in Asthma
zanubrutinibBrukinsaBeOne Medicinessmall moleculeApprovedApproved in Chronic Lymphocytic Leukemia; Approved in Follicular Lymphoma; Approved in Mantle Cell Lymphoma

← all mechanisms